Carbiogene Therapeutics Co. Ltd.
anti-BCMA CAR-T(Carbiogene Therapeutics Co. Ltd.)은 BCMA 표적 세포·유전자 치료로, Multiple Myeloma 영역에서 개발·상용화 중입니다. 작용기전: CAR T cells (low CAR T-induced killing rate). Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 97.1% (ClinicalTrials.gov NCT03548207). 차별점: unique challenges, particularly concerning ocular toxicity.
BCMA
Multiple Myeloma
Active
CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinica
lentiviral vector encoding a humanized anti-B cell maturation antigen (BCMA) CAR, in adult
humanized anti-B cell maturation antigen (BCMA) CAR, in adults with relapsed or refractory multiple myeloma
unique challenges, particularly concerning ocular toxicity
CAR T cells (low CAR T-induced killing rate)
Cytokine release syndrome occurred in four patients (three grade 3 and one grade 2) and was managed with corticoster
biomarkers to predict and identify factors associated with response and relapse
bypass ex vivo manufacturing and lymphodepletion, potentially simplifying and accelerating access to cellular therapy; prelimi
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Carbiogene Therapeutics Co. Ltd.
anti-BCMA CAR-T(Carbiogene Therapeutics Co. Ltd.)은 BCMA 표적 세포·유전자 치료로, Multiple Myeloma 영역에서 개발·상용화 중입니다. 작용기전: CAR T cells (low CAR T-induced killing rate). Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 97.1% (ClinicalTrials.gov NCT03548207). 차별점: unique challenges, particularly concerning ocular toxicity.
BCMA
Multiple Myeloma
Active
CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinica
lentiviral vector encoding a humanized anti-B cell maturation antigen (BCMA) CAR, in adult
humanized anti-B cell maturation antigen (BCMA) CAR, in adults with relapsed or refractory multiple myeloma
unique challenges, particularly concerning ocular toxicity
CAR T cells (low CAR T-induced killing rate)
Cytokine release syndrome occurred in four patients (three grade 3 and one grade 2) and was managed with corticoster
biomarkers to predict and identify factors associated with response and relapse
bypass ex vivo manufacturing and lymphodepletion, potentially simplifying and accelerating access to cellular therapy; prelimi
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.